Menu

CancerCare

Apollo Hospitals Boosts Digital Oncology with Acquisition

Apollo Hospitals Boosts Digital Oncology with Acquisition

Apollo Hospitals Boosts Digital Oncology with Acquisition

With the strategic acquisition of cancer care platform Onco, Apollo Hospitals deepens its digital healthcare capabilities as it gears up for the demerger of Apollo HealthCo.

Summary:
Apollo Hospitals has quietly acquired healthtech startup Onco, which is backed by marquee investors like Accel and Rainmatter. While the financial terms remain undisclosed, sources confirm that the deal was closed in December 2024. This acquisition reinforces Apollo’s growing focus on digital healthcare and cancer care, especially as it prepares for the demerger of its pharmacy and digital platform arm, Apollo HealthCo.

Apollo Hospitals Expands Its Digital Health Footprint
India’s healthcare giant, Apollo Hospitals, has taken a strategic step forward in its digital transformation journey with the acquisition of Onco, a healthtech startup that offers end-to-end cancer care services. While the financial details of the transaction have not been officially disclosed, sources close to the matter revealed that the deal was completed in December 2024.
The acquisition marks a significant milestone in Apollo’s plan to strengthen its digital healthcare capabilities, particularly in oncology, a field that continues to see rising demand and innovation.

About Onco: Empowering Personalised Cancer Care
Founded in 2016 by Dr. Amit Jotwani, an oncologist, and Siddhartha Jain, a former VC and entrepreneur, Onco.com was designed to simplify and democratize cancer treatment by providing patients with access to expert advice, personalised treatment plans, and coordinated care services.
Over the years, Onco has built a robust ecosystem that includes:
– A virtual tumour board to provide multi-disciplinary opinions
– A care management team that supports patients throughout their treatment
– A service that links patients to oncologists, medical facilities, and diagnostic laboratories.
The platform has served over 100,000 cancer patients across India and abroad, becoming a go-to resource for people looking for trusted and comprehensive cancer support. Its services span various stages of cancer, from diagnosis and treatment to post-treatment care and second opinions.

Backed by Prominent Investors
Onco has secured more than $13 million from prominent investors, including:
– Accel (a leading early-stage VC firm)
– Rainmatter Capital (backed by Zerodha)
– Vijay Shekhar Sharma, founder of Paytm
– Alteria Capital
– Prime Venture Partners
These funds helped Onco build its core technology platform, expand its team of oncologists and care managers, and build a data-rich oncology ecosystem.

Why Apollo’s Acquisition Makes Strategic Sense
The acquisition of Onco aligns perfectly with Apollo’s broader vision to dominate the digital health ecosystem. Apollo has been increasingly investing in technology, AI-driven diagnostics, telemedicine, and remote monitoring as part of its digital-first strategy.
Here’s why the Onco acquisition is a perfect strategic fit:
1. Deep Oncology Expertise: Apollo already has a strong presence in cancer treatment with its Apollo Cancer Centres. Onco adds a tech-driven layer that makes cancer care more accessible, affordable, and efficient.
2. Patient-Centric Digital Model: Onco’s platform-centric approach complements Apollo’s digital strategy to provide end-to-end patient journeys — from consultation and diagnosis to treatment and recovery.
3. Data-Driven Insights: With Onco’s oncology-focused patient data, Apollo can now enhance clinical decision-making and personalised treatment through AI and predictive analytics.
4. Synergy with Apollo HealthCo: The acquisition happens at a vital moment as Apollo works on spinning off Apollo HealthCo, its pharmacy distribution and digital health division, into a separate entity.

Apollo HealthCo Demerger in Focus
Apollo Hospitals has been streamlining its operations and sharpening its focus on vertical-specific growth. One of the biggest transformations in progress is the demerger of Apollo HealthCo, which combines its:
-Offline & digital pharmacy operations
-Digital consultation platform (Apollo 24|7)
-Telemedicine and diagnostics
The newly formed entity will focus on tech-enabled omnichannel healthcare services and is expected to attract its investor base. Acquisitions like Onco add significant value to HealthCo’s offerings, enhancing its clinical depth, patient experience, and platform scalability.

Rising Demand for Oncology Solutions
Cancer cases in India are expected to increase greatly, with the Indian Council of Medical Research (ICMR) projecting more than 1.5 million new cases each year by 2025. Limited access to high-quality care in Tier 2 and Tier 3 cities has driven the need for digital oncology solutions like Onco.
By integrating Onco into its ecosystem, Apollo Hospitals can now offer remote cancer consultations, personalised care plans, and cross-speciality collaboration at scale — a critical value proposition for India’s growing cancer burden.

What This Means for the Healthcare Sector
The Apollo-Onco deal signals a growing trend where large hospital chains are acquiring niche healthtech startups to accelerate innovation, improve service delivery, and reach new markets. As the lines between physical and digital healthcare continue to blur, such mergers will become more common.
Startups with deep specialisation in one vertical (like cancer, fertility, mental health, or chronic disease) are becoming prime acquisition targets for larger healthcare conglomerates looking to quickly expand their capabilities.

Future Outlook
With this acquisition, Apollo Hospitals is poised to strengthen its leadership in the oncology space while driving forward its digital health mission. It also sets the stage for Apollo HealthCo to emerge as a tech-powered, patient-first healthcare platform that can potentially list independently or attract strategic investors shortly.
The integration of Onco will likely fuel innovation in care delivery, improve patient navigation in complex cases, and contribute to building India’s most comprehensive and tech-savvy oncology network.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The image added is for representation purposes only

Tata Sons Strengthens Hold on Tata Capital: Shaping the Future of India’s Banking and Financial Sector

WhiteHat Jr Founder Secures $16M for US Cancer Care Venture, Complement1

WhiteHat Jr Founder Secures $16M for US Cancer Care Venture, Complement1

WhiteHat Jr Founder Secures $16M for US Cancer Care Venture, Complement1

 

From coding education to cancer care, Karan Bajaj’s new venture aims to transform oncology outcomes through tech-enabled, personalized lifestyle coaching.

A New Chapter: From Edtech to Healthtech

Karan Bajaj, renowned for founding WhiteHat Jr-a platform that taught coding to children and was acquired by BYJU’S for $300 million in 2020-has shifted his entrepreneurial focus from education to healthcare. His latest venture, Complement1, is based in the United States and targets a critical gap in cancer care: the integration of evidence-based lifestyle interventions into the treatment and recovery process.
After his exit from BYJU’S in 2021 and a period of personal reflection, Bajaj returned to the startup scene with a mission to address the unmet needs of cancer patients, survivors, and those at high risk. Complement1 combines advanced technology, evidence-based clinical practices, and personalized coaching to deliver impactful and enduring benefits for patients.

Complement1: The Vision and Model
Personalized, Daily Support:
Complement1 offers individualized daily support to cancer patients and those at high risk through personalized sessions led by dedicated CoActive Coaches.
These coaches help users incorporate clinically recommended practices in nutrition, physical activity, sleep, and stress management-areas often overlooked in conventional cancer care.

Tech-Enabled, Clinically Validated:

The platform leverages an AI-driven personalization engine to tailor interventions and education for each user. Complement1’s approach is backed by clinical studies, showing outcomes such as a 37% reduction in treatment-related side effects, an 18% decrease in pain levels, and a 27% improvement in sleep quality for its members.
The program boasts over 90% adherence rates, a testament to its daily engagement strategy.
Integration with Healthcare Ecosystem:
Complement1 partners with cancer centers, health plans, and employers to make its platform available to a wider population. Early actuarial modeling suggests that its approach can reduce healthcare costs for cancer patients by up to 30%, benefiting not just individuals but also providers and insurers.

Funding and Growth Plans

Complement1 has secured $16 million in seed funding, led by Owl Ventures and Blume Ventures, along with support from unnamed investors. The funding will be directed toward:
• Expanding the company’s coaching capabilities and operational presence across the U.S.
• Developing its AI-powered personalization platform further
• Improving the digital interface for both users and coaching staff
• Building strategic collaborations with hospitals, insurance providers, and corporate partners
Amit A. Patel, Managing Director at Owl Ventures, commended Complement1 for its unique blend of advanced technology and personalized coaching, calling it a “game-changing approach to transforming cancer care outcomes worldwide.”

The Rise of Second-Time Founders

Bajaj’s journey reflects a growing trend in the Indian and global startup ecosystem, successful founders returning with new, often more ambitious ventures. After high-profile exits, many leaders are leveraging their experience and networks to tackle complex problems in sectors like healthtech, fintech, and sustainability. Bajaj’s shift from edtech to healthtech reflects a broader trend of adaptability and evolving vision among seasoned entrepreneurs.

Lessons from WhiteHat Jr

WhiteHat Jr’s meteoric rise and subsequent controversies-including aggressive marketing, regulatory scrutiny, and eventual shutdown-have shaped Bajaj’s approach to Complement1. This time, the emphasis is on clinical validation, compassionate engagement, and measurable impact. The startup’s initial outcomes and backing from investors indicate a promising base for long-term, scalable expansion.

Conclusion

Karan Bajaj’s Complement1 is poised to make a significant impact on cancer care by addressing the critical, yet often neglected, role of lifestyle interventions in treatment and recovery. With robust funding, a clinically validated approach, and a focus on personalized, tech-enabled coaching, Complement1 is set to redefine support for cancer patients and high-risk individuals. The venture not only marks Bajaj’s successful transition from edtech to healthtech but also signals a broader shift towards holistic, patient-centered care in the digital age.

 

 

 

 

 

 

The image added is for representation purposes only

BEL Sees Stock Rally After Akashteer Demonstration